Global Neuroendocrine Tumor Treatment Market Is
Estimated To Witness High Growth Owing To Increasing Research and Development
Activities & Growing Awareness among Patients



One key trend in the Neuroendocrine
Tumor Treatment Market is the growing focus on targeted therapy.
Targeted therapy involves the use of drugs or other substances that
specifically target cancer cells without harming normal cells. This approach
has shown promising results in neuroendocrine tumor treatment by improving
patient outcomes and reducing side effects.



For example, Lutathera, developed by Novartis AG's subsidiary Advanced
Accelerator Applications, is a first-in-class peptide receptor radionuclide
therapy indicated for the treatment of gastroenteropancreatic neuroendocrine
tumors. It specifically targets somatostatin receptors expressed on
neuroendocrine tumor cells, delivering radiation directly to the tumor site.